Table 5. Adverse events (>5% of patients); arm A: DG followed by erlotinib if progression, arm B: erlotinib followed by DG if progression.

	Arm A (n=48)		Arm B (n=51)
First line toxicity	Grade 1/2	Grade 3/4	Grade 1/2	Grade 3/4
Haematologic
Anaemia (%)	29 (60.4)	3 (6.3)	12 (23.5)	–
Neutropenia (%)	21 (43.8)	15 (31.3)	–	–
Thrombocytopenia (%)	16 (35.4)	3 (6.3)	–	–
Non haematologic
Cutaneous (%)	5 (10.5)	1 (2.1)	37 (72.6)	5 (9.8)
Asthenia (%)	33 (68.8)	3 (6.3)	15 (29.4)	4 (7.9)
Diarrhoea (%)	21 (43.7)	1 (2.1)	10 (19.6)	2 (4)
Constipation (%)	6 (12.5)	1 (2.1)	5 (9.8)	–
Nausea (%)	10 (20.9)	–	1 (2)	–
Vomiting (%)	11 (22.9)	–	6 (11.8)	–
Alopecia (%)	7 (14.6)	–	5 (9.8)	–
Pulmonary (%)	4 (8.4)	2 (4.2)	9 (17.6)	2 (4)
Peripheral neuropathy (%)	5 (10.4)	–	–	–
Anorexia (%)	4 (8.4%)	–	6 (11.8)	1 (2)

	Arm A (n=29)		Arm B (n=24)
Second line toxicity	Grade 1/2	Grade 3/4	Grade 1/2	Grade 3/4
Haematologic
Anaemia (%)	4 (13)	–	20 (83)	–
Neutropenia (%)	–	–	5 (20.8)	4 (16.6)
Thrombocytopenia (%)	2(5)	–	10 (41.6)	1 (3)
Non haematologic
Cutaneous (%)	13 (44)	–	2 (8.3)	1 (3)
Asthenia (%)	9 (31)	3 (10)	16 (55)	3 (12)
Diarrhoea (%)	3 (10.3)	–	4 (16.6)	–
Constipation (%)	1 (3.4)	–	7 (29.1)	–
Nausea (%)	2 (5)	–	6 (25)	–
Alopecia (%)	–	–	2 (8.3)	–
Pulmonary	2 (5)	–	5 (20)	3 (12)
Peripheral neuropathy (%)	–	–	2 (8.3)	–
Anorexia (%)	–	–	3 (12)	–

Abbreviation: DG=docetaxel and gemcitabine.